27 research outputs found
Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2
AbstractRecent studies have characterized the ABC half-transporter associated with mitoxantrone resistance in human cancer cell lines. Encoded by the ABCG2 gene, overexpression confers resistance to camptothecins, as well as to mitoxantrone. We developed four polyclonal antibodies against peptides corresponding to four different epitopes on the mitoxantrone resistance-associated protein, ABCG2. Three epitopes localized on the cytoplasmic region of ABCG2 gave rise to high-affinity antibodies, which were demonstrated to be specific for ABCG2. Western blot analysis of cells with high levels of ABCG2 showed a single major band of the expected 72-kDa molecular size of ABCG2 under denaturing conditions. Immunoblot analysis performed under non-reducing conditions and after treatment with cross-linking reagents demonstrated a molecular weight shift from 72 kDa to several bands of 180 kDa and higher molecular weight, suggesting detection of dimerization products of ABCG2. Evidence of N-linked glycosylation was also obtained using tunicamycin and N-glycosidase F. Finally, both by light, fluorescence and electron microscopic immunohistochemical staining, we demonstrate cytoplasmic and predominantly plasma membrane localization of ABCG2 in cell lines with high levels of expression. Plasma membrane staining was observed on the surface of the chorionic villi in placenta. These results support the hypothesis that ABCG2 is an ABC half-transporter that forms dimers in the plasma membrane, functioning as an ATP-dependent outward pump for substrate transport
Evidence for Human Adaptation and Foodborne Transmission of Livestock-Associated Methicillin-Resistant Staphylococcus aureus
We investigated the evolution and epidemiology of a novel livestock-associated methicillin-resistant Staphylococcus aureus strain, which colonizes and infects urban-dwelling Danes even without a Danish animal reservoir. Genetic evidence suggests both poultry and human adaptation, with poultry meat implicated as a probable source
Recommended from our members
Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define pre-malignant neurofibromatosis type 1-associated atypical neurofibromas
BackgroundNeurofibromatosis type 1 (NF1) is a tumor-predisposition disorder caused by germline mutations in NF1. NF1 patients have an 8-16% lifetime risk of developing a malignant peripheral nerve sheath tumor (MPNST), a highly aggressive soft-tissue sarcoma, often arising from preexisting benign plexiform neurofibromas (PNs) and atypical neurofibromas (ANFs). ANFs are distinct from both PN and MPNST, representing an intermediate step in malignant transformation.MethodsIn the first comprehensive genomic analysis of ANF originating from multiple patients, we performed tumor/normal whole-exome sequencing (WES) of 16 ANFs. In addition, we conducted WES of 3 MPNSTs, copy-number meta-analysis of 26 ANFs and 28 MPNSTs, and whole transcriptome sequencing analysis of 5 ANFs and 5 MPNSTs.ResultsWe identified a low number of mutations (median 1, range 0-5) in the exomes of ANFs (only NF1 somatic mutations were recurrent), and frequent deletions of CDKN2A/B (69%) and SMARCA2 (42%). We determined that polycomb repressor complex 2 (PRC2) genes EED and SUZ12 were frequently mutated, deleted, or downregulated in MPNSTs but not in ANFs. Our pilot gene expression study revealed upregulated NRAS, MDM2, CCND1/2/3, and CDK4/6 in ANFs and MPNSTs, and overexpression of EZH2 in MPNSTs only.ConclusionsThe PN-ANF transition is primarily driven by the deletion of CDKN2A/B. Further progression from ANF to MPNST likely involves broad chromosomal rearrangements and frequent inactivation of the PRC2 genes, loss of the DNA repair genes, and copy-number increase of signal transduction and cell-cycle and pluripotency self-renewal genes
Human–Mouse Chimeras with Normal Expression and Function Reveal That Major Domain Swapping Is Tolerated by P‑Glycoprotein (ABCB1)
The
efflux transporter P-glycoprotein (P-gp) plays a vital role
in the transport of molecules across cell membranes and has been shown
to interact with a panoply of functionally and structurally unrelated
compounds. How human P-gp interacts with this large number of drugs
has not been well understood, although structural flexibility has
been implicated. To gain insight into this transporter’s broad
substrate specificity and to assess its ability to accommodate a variety
of molecular and structural changes, we generated human–mouse
P-gp chimeras by the exchange of homologous transmembrane and nucleotide-binding
domains. High-level expression of these chimeras by BacMam- and baculovirus-mediated
transduction in mammalian (HeLa) and insect cells, respectively, was
achieved. There were no detectable differences between wild-type and
chimeric P-gp in terms of cell surface expression, ability to efflux
the P-gp substrates rhodamine 123, calcein-AM, and JC-1, or to be
inhibited by the substrate cyclosporine A and the inhibitors tariquidar
and elacridar. Additionally, expression of chimeric P-gp was able
to confer a paclitaxel-resistant phenotype to HeLa cells characteristic
of P-gp-mediated drug resistance. P-gp ATPase assays and photo-cross-linking
with [<sup>125</sup>I]Âiodoarylazidoprazosin confirmed that transport
and biochemical properties of P-gp chimeras were similar to those
of wild-type P-gp, although differences in drug binding were detected
when human and mouse transmembrane domains were combined. Overall,
chimeras with one or two mouse P-gp domains were deemed functionally
equivalent to human wild-type P-gp, demonstrating the ability of human
P-gp to tolerate major structural changes
Human–Mouse Chimeras with Normal Expression and Function Reveal That Major Domain Swapping Is Tolerated by P‑Glycoprotein (ABCB1)
The
efflux transporter P-glycoprotein (P-gp) plays a vital role
in the transport of molecules across cell membranes and has been shown
to interact with a panoply of functionally and structurally unrelated
compounds. How human P-gp interacts with this large number of drugs
has not been well understood, although structural flexibility has
been implicated. To gain insight into this transporter’s broad
substrate specificity and to assess its ability to accommodate a variety
of molecular and structural changes, we generated human–mouse
P-gp chimeras by the exchange of homologous transmembrane and nucleotide-binding
domains. High-level expression of these chimeras by BacMam- and baculovirus-mediated
transduction in mammalian (HeLa) and insect cells, respectively, was
achieved. There were no detectable differences between wild-type and
chimeric P-gp in terms of cell surface expression, ability to efflux
the P-gp substrates rhodamine 123, calcein-AM, and JC-1, or to be
inhibited by the substrate cyclosporine A and the inhibitors tariquidar
and elacridar. Additionally, expression of chimeric P-gp was able
to confer a paclitaxel-resistant phenotype to HeLa cells characteristic
of P-gp-mediated drug resistance. P-gp ATPase assays and photo-cross-linking
with [<sup>125</sup>I]Âiodoarylazidoprazosin confirmed that transport
and biochemical properties of P-gp chimeras were similar to those
of wild-type P-gp, although differences in drug binding were detected
when human and mouse transmembrane domains were combined. Overall,
chimeras with one or two mouse P-gp domains were deemed functionally
equivalent to human wild-type P-gp, demonstrating the ability of human
P-gp to tolerate major structural changes